Cardiff Oncology Director Gary Pace Acquires $36,600 in Shares Amid Clinical and Licensing Developments
Gary W. Pace, a director at Cardiff Oncology, Inc. (NASDAQ: CRDF), has purchased 30,000 shares of the company's common stock, according to a recent filing with the Securities and Exchange Commission (SEC). The transaction, valued at $36,600, was executed on June 18, 2026, at a price of $1.22 per share. This purchase brings Pace's direct ownership t…